The Research Behind Our Products.
Our formulations have been evaluated through clinical studies, published research, and physician-led scientific review focused on digestive health and gastrointestinal function.
This body of research includes independent university investigations, published clinical data, and practice-based analyses involving patients with persistent digestive symptoms.
Northwestern University Feinberg School of Medicine Study
An independent study conducted at Northwestern University Feinberg School of Medicine evaluated Atrantil in patients experiencing gastrointestinal symptoms associated with methane-producing microbes.
In this study:
• 56% of participants reported adequate symptom relief
• Outcomes were measured across seven symptom categories
• Participants were enrolled with minimal exclusion criteria to reflect real-world patients
Additional study details:
The study was led by Darren Brenner, MD, FACG, AGAF
Conducted independently of KBS Research and its partners
Double-Blind Clinical Study
A double-blind clinical trial evaluated Atrantil in patients experiencing bloating, constipation, and abdominal discomfort.
In this study:
• 88% of patients experienced symptom improvement
Additional study details:
• Randomized, double-blind study design
Evaluated key gastrointestinal symptoms, including bloating and abdominal discomfort
The study was published in:
Journal of Gastroenterology and Hepatology Research September 21, 2015
Open-Label Study
An open-label clinical study evaluated Atrantil in patients with persistent digestive symptoms who had not responded to previous treatments.
In this study:
• 80% of patients reported symptom improvement
Additional study details:
Participants had previously failed multiple therapies
Evaluated real-world patients with ongoing symptoms
The study was published in: World Journal of Gastrointestinal Pharmacology and Therapeutics August 6, 2016
Additional study details:
The study was led by Darren Brenner, MD, FACG, AGAF
Conducted independently of KBS Research and its partners
Retrospective Clinical Study (GERD)
A retrospective chart analysis published in the Open Journal of Gastroenterology evaluated a polyphenol-based nutraceutical (Re:flux) in patients with chronic GERD.
In this study:
• 81% of patients reported complete symptom resolution
• 91.5% of patients experienced clinically meaningful improvement (≥75%)
• All patients reporting bloating at baseline experienced improvement by week 79.3% of patients discontinued acid-suppressing medications
The study was published in: Open Journal of Gastroenterology March 17, 2026
Additional study details:
• Patients had confirmed chronic GERD via endoscopy
• Participants discontinued PPIs and H2 blockers prior to treatment
• Outcomes were measured over a 4-week period using structured symptom scoring
• Compared nutraceutical group (n=47) vs usual care (n=25)